^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:225Ac-FL-020 (Ionizing radiation emitter, PSMA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    PRNewswire
    Title:

    Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    Published date:
    07/02/2024
    Excerpt:
    Full-Life Technologies...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 225Ac-FL-020, the company's lead radiopharmaceutical, which targets prostate-specific membrane antigen (PSMA), for the treatment of metastatic castration-resistant prostate cancer (mCRPC).